Liver Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016 - GlobalData

Liver Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016

Liver Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016 - GlobalData
Liver Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016
Published Sep 14, 2016
94 pages — Published Sep 14, 2016
Price US$ 4,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GlobalData's Medical Devices sector report, Liver Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016' provides an overview of Liver Cancer Diagnostic Tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Liver Cancer Diagnostic Tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Liver Cancer Diagnostic Tests under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Liver Cancer Diagnostic Tests and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Liver Cancer Diagnostic Tests under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the products current stage of development, territory and estimated launch date

  
Source:
Document ID
GDME0221EPD
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
1 Table of Contents27
  1.1 List of Tables53
  1.2 List of Figures81
2 Introduction91
  2.1 Liver Cancer Diagnostic Tests Overview91
3 Products under Development104
  3.1 Liver Cancer Diagnostic Tests - Pipeline Products by Stage of Development101
  3.2 Liver Cancer Diagnostic Tests - Pipeline Products by Territory111
  3.3 Liver Cancer Diagnostic Tests - Pipeline Products by Regulatory Path121
  3.4 Liver Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date131
4 Liver Cancer Diagnostic Tests - Pipeline Products under Development by Companies144
  4.1 Liver Cancer Companies - Pipeline Products by Stage of Development142
  4.2 Liver Cancer Diagnostic Tests - Pipeline Products by Stage of Development162
5 Liver Cancer Diagnostic Tests Companies and Product Overview1846
  5.1 Abbott Diagnostics Company Overview181
    5.1.1 Abbott Diagnostics Pipeline Products &Ongoing Clinical Trials Overview185
  5.2 Abcodia Ltd. Company Overview231
    5.2.1 Abcodia Ltd. Pipeline Products &Ongoing Clinical Trials Overview231
  5.3 AXO Science S.A.S. Company Overview241
    5.3.1 AXO Science S.A.S. Pipeline Products &Ongoing Clinical Trials Overview243
  5.4 BioMark Technologies Inc. Company Overview271
    5.4.1 BioMark Technologies Inc. Pipeline Products &Ongoing Clinical Trials Overview271
  5.5 China Sky One Medical, Inc. Company Overview281
    5.5.1 China Sky One Medical, Inc. Pipeline Products &Ongoing Clinical Trials Overview281
  5.6 Digna Biotech, S.L. Company Overview291
    5.6.1 Digna Biotech, S.L. Pipeline Products &Ongoing Clinical Trials Overview292
  5.7 Drexel University Company Overview311
    5.7.1 Drexel University Pipeline Products &Ongoing Clinical Trials Overview312
  5.8 German Cancer Research Center Company Overview331
    5.8.1 German Cancer Research Center Pipeline Products &Ongoing Clinical Trials Overview331
  5.9 Glycotest, Inc. Company Overview341
    5.9.1 Glycotest, Inc. Pipeline Products &Ongoing Clinical Trials Overview341
  5.10 Imperial College London Company Overview351
    5.10.1 Imperial College London Pipeline Products &Ongoing Clinical Trials Overview351
  5.11 IntegraGen SA Company Overview361
    5.11.1 IntegraGen SA Pipeline Products &Ongoing Clinical Trials Overview362
  5.12 Matrix-Bio, Inc. Company Overview381
    5.12.1 Matrix-Bio, Inc. Pipeline Products &Ongoing Clinical Trials Overview382
  5.13 NanoString Technologies, Inc. Company Overview401
    5.13.1 NanoString Technologies, Inc. Pipeline Products &Ongoing Clinical Trials Overview402
  5.14 National Cancer Institute Company Overview421
    5.14.1 National Cancer Institute Pipeline Products &Ongoing Clinical Trials Overview422
  5.15 Oncimmune (USA) LLC Company Overview441
    5.15.1 Oncimmune (USA) LLC Pipeline Products &Ongoing Clinical Trials Overview441
  5.16 Orion Genomics LLC Company Overview451
    5.16.1 Orion Genomics LLC Pipeline Products &Ongoing Clinical Trials Overview451
  5.17 PleX Diagnostics Company Overview461
    5.17.1 PleX Diagnostics Pipeline Products &Ongoing Clinical Trials Overview461
  5.18 ProMIS Neurosciences Inc. Company Overview471
    5.18.1 ProMIS Neurosciences Inc. Pipeline Products &Ongoing Clinical Trials Overview472
  5.19 Proplex Technologies, Llc Company Overview491
    5.19.1 Proplex Technologies, Llc Pipeline Products &Ongoing Clinical Trials Overview491
  5.20 Proteome Sciences Plc Company Overview501
    5.20.1 Proteome Sciences Plc Pipeline Products &Ongoing Clinical Trials Overview502
  5.21 Roche Diagnostics International Ltd. Company Overview521
    5.21.1 Roche Diagnostics International Ltd. Pipeline Products &Ongoing Clinical Trials Overview521
  5.22 TrovaGene, Inc. Company Overview531
    5.22.1 TrovaGene, Inc. Pipeline Products &Ongoing Clinical Trials Overview532
  5.23 University of Rochester Company Overview551
    5.23.1 University of Rochester Pipeline Products &Ongoing Clinical Trials Overview551
  5.24 Ventana Medical Systems, Inc. Company Overview561
    5.24.1 Ventana Medical Systems, Inc. Pipeline Products &Ongoing Clinical Trials Overview561
  5.25 Viomics Inc. Company Overview571
    5.25.1 Viomics Inc. Pipeline Products &Ongoing Clinical Trials Overview571
  5.26 XEPTAGEN SpA Company Overview581
    5.26.1 XEPTAGEN SpA Pipeline Products &Ongoing Clinical Trials Overview585
  5.27 Xiamen Zeesan Biotech Co.,Ltd Company Overview631
    5.27.1 Xiamen Zeesan Biotech Co.,Ltd Pipeline Products &Ongoing Clinical Trials Overview631
6 Liver Cancer Diagnostic Tests - Recent Developments6427
  6.1 Aug 12, 2016: ProMIS Neurosciences Announces Second Quarter 2016 Results641
  6.2 Aug 09, 2016: Blueprint Medicines Reports Second Quarter 2016 Financial Results651
  6.3 Aug 04, 2016: Trovagene Reports Second Quarter 2016 Financial Results and Accomplishments661
  6.4 Aug 04, 2016: PerkinElmer Announces Financial Results for the Second Quarter of 2016671
  6.5 Aug 03, 2016: NanoString Technologies Releases Operating Results for Second Quarter of 2016681
  6.6 Aug 02, 2016: Pfizer Reports Second-Quarter 2016 Results695
  6.7 Jul 27, 2016: PerkinElmer Elects Frank Witney to Board of Directors741
  6.8 Jul 13, 2016: Pfizer and NovaMedica announce a strategic partnership in Russia741
  6.9 Jul 12, 2016: PerkinElmer Raises USD552.3 Million in Public Offering of 1.875% Senior Notes Due 2026751
  6.10 Jul 07, 2016: IntegraGen reports strong revenue growth during first half of 2016761
  6.11 Jul 04, 2016: Oncimmune Enters into Research Agreement with Egybiotech and Aarhus University Hospital761
  6.12 Jun 27, 2016: ProMIS Neurosciences Raises USD0.8 Million in Private Placement of Units761
  6.13 Jun 23, 2016: Oncimmune Appoints Julian Hirst as Non-Executive Director771
  6.14 Jun 16, 2016: Pfizer Breaks Ground On New Biologics Clinical Manufacturing Facility In Andover, Massachusetts771
  6.15 Jun 02, 2016: NanoString Technologies Highlights Advances in Precision Oncology and Immunotherapy at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO)783
  6.16 Jun 01, 2016: Royal Philips Enters into Research Agreement with Yale School of Medicine811
  6.17 Jun 01, 2016: Proteome Sciences Announces CEO Appointment811
  6.18 May 31, 2016: Pfizer Raises USD1.25 Billion in Public Offering of 1.2% Notes Due 2018821
  6.19 May 31, 2016: Pfizer Raises USD0.85 Billion in Public Offering of 1.45% Notes Due 2019821
  6.20 May 31, 2016: Pfizer Raises USD1.15 Billion in Public Offering of 1.95% Notes Due 2021831
  6.21 May 31, 2016: Pfizer Raises USD1.25 Billion in Public Offering of 2.75% Notes Due 2026831
  6.22 May 31, 2016: Pfizer Raises USD0.5 Billion in Public Offering of 4.4% Notes Due 2044841
  6.23 May 11, 2016: ProMIS Neurosciences announces first quarter 2016 results841
  6.24 May 10, 2016: Trovagene Announces First Quarter 2016 Financial Results851
  6.25 May 10, 2016: Blueprint Medicines Reports First Quarter 2016 Financial Results862
  6.26 Apr 27, 2016: A.G. Schneiderman Announces Multistate And Federal Settlement With Wyeth And Pfizer For $784.6m To Resolve Allegations Of Underpaying Rebates Owed Through The Medicaid Drug Rebate Program881
  6.27 Mar 07, 2016: Blueprint Medicines Enters into Co-Development Agreement with Ventana Medical Systems891
  6.28 Dec 02, 2015: Surefire Medical Raises USD15 Million in Series C Financing891
  6.29 Oct 27, 2015: Simple blood test measures risk of liver cancer891
  6.30 Sep 21, 2015: Veran Medical Raises USD30.6 Million in Venture Financing901
  6.31 Sep 09, 2015: Quirem Medical Raises Funds through Private Placement of Shares901
7 Appendix914
  7.1 Methodology912
  7.2 About GlobalData931
  7.3 Contact Us941
  7.4 Disclaimer941

Table Of Contents

GlobalData—GlobalData uses proprietary data sources, tools and techniques to gather, analyze and represent the latest and the most reliable information essential for a business to sustain a competitive edge. GlobalData is a comprehensive source of insights and analysis with coverage across the oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries.

About the Author


Cite this Report

  
MLA:
GlobalData. "Liver Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016" Sep 14, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GlobalData/Liver-Cancer-Diagnostic-Tests-Medical-Devices-Pipeline-Assessment-2016-2085-23612>
  
APA:
GlobalData. (2016). Liver Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016 Sep 14, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GlobalData/Liver-Cancer-Diagnostic-Tests-Medical-Devices-Pipeline-Assessment-2016-2085-23612>
  
US$ 4,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.